Literature DB >> 32081555

Rates of substance use disorder treatment seeking visits after emergency department-initiated buprenorphine.

Lindsey K Jennings1, Carolyn Bogan2, Jenna J McCauley3, Angela Moreland4, Suzanne Lane5, Ralph Ward6, Karen J Hartwell7, Louise Haynes8, Kathleen T Brady9.   

Abstract

BACKGROUND: Emergency department-initiated buprenorphine (EDIB) programs have been shown to improve treatment outcomes for patients with opioid use disorders (OUD); however, little is known about how EDIB implementation impacts the patient census at participating hospitals.
OBJECTIVES: To determine if implementation of an EDIB program was associated with changes in the number of patients presenting to the ED seeking treatment for substance use disorder (SUD).
METHODS: We conducted a retrospective evaluation at a single academic ED that began offering EDIB in December 2017. Data span the period of December 2016 to April 2019, All ED visits with a chief complaint of addiction problem, detoxification, drug/alcohol assessment, drug problem, or withdrawal charted by nursing at the time of triage were eligible for inclusion. Charts were reviewed to determine: (1) treatment status and (2) substance(s) for which the patient was seeking treatment. An interrupted time series analysis was used to compare the pre- and post-EDIB rates for all-substance, as well as opioid-specific, treatment-seeking visits.
RESULTS: For all-substance visits, the predicted level change in the treatment-seeking rate after EDIB was implemented was positive but not significant (0.000497, p = 0.53); the trend change after EDIB was also not significant (-0.00004, p = 0.73). For visits involving opioids, the predicted level change was (0.000638, p = 0.21); and the trend change was (0.000047, p = 0.49).
CONCLUSION: Implementation of an EDIB program was not associated with increased rates of presentation by patients requesting treatment for a substance use disorder in the participating ED setting.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Access to care; Buprenorphine; Emergency medicine; Health care utilization; Opioid addiction; Opioid use disorder

Mesh:

Substances:

Year:  2020        PMID: 32081555      PMCID: PMC7884203          DOI: 10.1016/j.ajem.2020.02.011

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  4 in total

1.  Segmented regression analysis of interrupted time series studies in medication use research.

Authors:  A K Wagner; S B Soumerai; F Zhang; D Ross-Degnan
Journal:  J Clin Pharm Ther       Date:  2002-08       Impact factor: 2.512

2.  Lessons from the past.

Authors:  Leonard Paulozzi; Ann Dellinger; Linda Degutis
Journal:  Inj Prev       Date:  2011-12-30       Impact factor: 2.399

3.  Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.

Authors:  Marc R Larochelle; Dana Bernson; Thomas Land; Thomas J Stopka; Na Wang; Ziming Xuan; Sarah M Bagley; Jane M Liebschutz; Alexander Y Walley
Journal:  Ann Intern Med       Date:  2018-06-19       Impact factor: 25.391

4.  Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial.

Authors:  Gail D'Onofrio; Patrick G O'Connor; Michael V Pantalon; Marek C Chawarski; Susan H Busch; Patricia H Owens; Steven L Bernstein; David A Fiellin
Journal:  JAMA       Date:  2015-04-28       Impact factor: 56.272

  4 in total
  2 in total

1.  Improving transitions of care for patients initiated on buprenorphine for opioid use disorder from the emergency departments in King County, Washington.

Authors:  Callan Elswick Fockele; Herbert C Duber; Brad Finegood; Sophie C Morse; Lauren K Whiteside
Journal:  J Am Coll Emerg Physicians Open       Date:  2021-03-23

2.  Advancing emergency department-initiated buprenorphine.

Authors:  Kristen Huntley; Emily Einstein; Terri Postma; Anita Thomas; Shari Ling; Wilson Compton
Journal:  J Am Coll Emerg Physicians Open       Date:  2021-06-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.